AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18389339
Drug: Benidipine administered
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine administered orally for 4 weeks
Trial: 18389339
Drug: Benidipine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine with L-arginine
Trial: 8181831
Drug: Porous hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous hydroxyapatite in granules (HA-G)
Trial: 3083212
Drug: Sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbinil (250 mg qd)
Trial: 29572130
Drug: Telephone-delivered exercise
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered exercise therapy by physiotherapists
Trial: 24894077
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (individual HT and CD-based HT)
Trial: 18231889
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus acupuncture (n=125)
Trial: 18231889
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus specific stabilising exercises (n=131)
Trial: 18231889
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (n=130)
Trial: 8831438
Drug: Lithium doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium doses adjusted to achieve a serum lithium concentration of 0.8 to 1.0 mmol/liter (standard)
Trial: 8831438
Drug: Lithium doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium doses adjusted to achieve a serum lithium concentration of 0.4 to 0.6 mmol/liter (low)
Trial: 1426392
Drug: Subconjunctival antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival antibiotics and steroids
Trial: 1426392
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics and steroids
Trial: 3897156
Drug: Mixed-beam treatment
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-beam treatment (neutron/photon)
Trial: 3897156
Drug: Photon radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photon radiation therapy (X ray)
Trial: 27392137
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg daily
Trial: 23361084
Drug: secukinumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab (10 mg/kg)
Trial: 8168348
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg twice daily for 7 days
Trial: 28364504
Drug: Tiagabine 12
RxNorm normalized name: tiaGABine 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine 12 mg
Trial: 22082303
Drug: Alkalinized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine and heparin
Trial: 19708504
Drug: 131I treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I treatment with oral methyloprednisolone (MP) over 30 days starting at 16 mg/day
Trial: 19708504
Drug: 131I treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I treatment
Trial: 17536225
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment adjustment (increase or decrease)
Trial: 17536225
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (41 matched patients, treatment unchanged)
Trial: 17536225
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (adjusted treatment)
Trial: 15601804
Drug: Bosentan 31.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 31.25 mg
Trial: 15601804
Drug: Bosentan 62.5
RxNorm normalized name: bosentan 62.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg
Trial: 24656288
Drug: Bosentan 125
RxNorm normalized name: bosentan 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan 125 mg
Trial: 15601804
Drug: Bosentan 250
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 250 mg
Trial: 10392325
Drug: Bosentan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (all doses)
Trial: 11860412
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g (LAC)
Trial: 11860412
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg (LMC)
Trial: 10453438
Drug: Combination low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low fat and low energy diet
Trial: 2216204
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg prostaglandin E2 gel intracervically (N = 52)
Trial: 2216204
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg prostaglandin E2 gel intravaginally (N = 48)
Trial: 350861
Drug: Penfluridol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penfluridol (administered once weekly)
Trial: 350861
Drug: Trifluoperazine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluoperazine (administered daily)
Trial: 28235027
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ALVAC-HIV and AIDSVAX B/E gp120
Trial: 17413093
Drug: Soymilk diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk diet (37.5 g/d)
Trial: 15197520
Drug: Intravenous desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous desmopressin (2 microg)
Trial: 15197520
Drug: Oral desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral desmopressin (0.2 mg)
Trial: 15197520
Drug: Daytime intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime intravenous desmopressin (2 microg)
Trial: 15197520
Drug: Daytime oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime oral desmopressin (0.2 mg)
Trial: 9569997
Drug: Avitriptan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan 50 mg under fasting conditions
Trial: 9569997
Drug: Avitriptan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan 50 mg after a high-fat breakfast
Trial: 3073524
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g four times daily for up to 12 weeks)
Trial: 3073524
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g four times daily for up to 12 weeks)
Trial: 28245243
Drug: Serelaxin intravenous
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin intravenous infusion (80 μg/kg/d for 60 min, then 30 μg/kg/d for 60 min)
Trial: 28245243
Drug: Terlipressin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (single 2-mg i.v. bolus)
Trial: 23509083
Drug: Homologous platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous platelet gel (PG)
Trial: 9602198
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide 1 mg every 12 hours for 5 days, then 500 micrograms every 12 hours for a total of 6 weeks
Trial: 2537699
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 5 mg benazepril hydrochloride
Trial: 4909817
Drug: Carbenoxolone sodium
RxNorm normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone sodium capsules (50 mg, four times a day for 12 weeks)
Trial: 4909817
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (capsule identical in every respect except that it did not contain carbenoxolone)
Trial: 26052147
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g Beta-Alanine (BA) + 34 g dextrose
Trial: 26052147
Drug: Placebo (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (34 g dextrose)
Trial: 23719347
Drug: Low birth
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birth weight (2000-2499 g)
Trial: 19536128
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg once daily)
Trial: 16295054
Drug: Pulsating electrostatic
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsating electrostatic field (PESF) therapy, 30 min daily exposure, adjusted between 2 and 9 kV
Trial: 15332347
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg/day upon awakening
Trial: 15332347
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg/day at bedtime
Trial: 15332347
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg/day at bedtime (polytherapy)
Trial: 1402213
Drug: Indobufen (INB)
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (INB) 400 mg daily
Trial: 1402213
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 900 mg daily plus dipyridamole (DP) 225 mg daily
Trial: 29286989
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy-based stress management program for 10 weeks
Trial: 26137881
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) in rash subgroup
Trial: 23811987
Drug: Desmopressin orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin orally disintegrating tablet (ODT)
Trial: 10591433
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin
Trial: 23811987
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin to desmopressin ODT
Trial: 21692282
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus herbal medicine
Trial: 11681532
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and 5-fluorouracil
Trial: 9779028
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg every 12 h subcutaneously
Trial: 9779028
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) as a continuous intravenous infusion
Trial: 25359424
Drug: Oral T3
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral T3 treatment (20 μg per day for 3 months)
Trial: 22819624
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg clonazepam
Trial: 22819624
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg clonazepam
Trial: 17547048
Drug: Regimen-1: albendazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-1: albendazole 800 mg/day twice daily for 3 consecutive days
Trial: 17547048
Drug: Regimen-2: albendazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-2: albendazole 800 mg/day twice daily for 5 consecutive days
Trial: 9405962
Drug: Tianeptine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (12.5 mg t.i.d)
Trial: 8199696
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg/day) and Ursodeoxycholic acid (600 mg/day)
Trial: 23816723
Drug: Control (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (neither drug)
Trial: 31173870
Drug: Yogliptin 2.5-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogliptin 2.5-600 mg
Trial: 31173870
Drug: Yogliptin 25-400
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogliptin 25-400 mg
Trial: 31173870
Drug: Yogliptin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogliptin 400 mg
Trial: 17237134
Drug: Carvedilol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (up to 25 mg twice a day)
Trial: 14963054
Drug: Low-soluble fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-soluble fiber diet (0.4 g added soluble fiber/2800 kcal)
Trial: 14963054
Drug: Medium-soluble fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-soluble fiber diet (3 g added soluble fiber/2800 kcal)
Trial: 14963054
Drug: High-soluble fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soluble fiber diet (6 g added soluble fiber/2800 kcal)
Trial: 8979210
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Coping Skills Therapy
Trial: 8979210
Drug: Twelve-Step Facilitation
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twelve-Step Facilitation Therapy
Trial: 8979210
Drug: 12-step facilitation
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-step facilitation treatment
Trial: 3662056
Drug: naloxone 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 0.08 mg IV every 2 min
Trial: 3662056
Drug: nalbuphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 2.5 mg IV every 2 min
Trial: 25541821
Drug: Azithromycin: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin: 500 mg once per day for 3 days + standard medical care
Trial: 25541821
Drug: Azithromycin: 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin: 500 mg once per day for 7 days, followed by 500 mg once per week for 12 weeks + standard medical care
Trial: 15823180
Drug: Calf muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf muscle energy metabolism in COPD patients
Trial: 15823180
Drug: Calf muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf muscle energy metabolism in control subjects
Trial: 12435217
Drug: Isoflavone preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone preparations
Trial: 7867177
Drug: 0.4 mg/h
RxNorm normalized name: nitroglycerin 0.4 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/h GTN skin patch
Trial: 3969339
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL of ferrous sulfate (FeSO4) drops (about 3 mg of iron per kilogram per day) for 3 months
Trial: 3969339
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL of ferrous sulfate (FeSO4) drops
Trial: 28913896
Drug: Topical non-azole
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical non-azole solution applied to one paw
Trial: 22124101
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (15 mg/kg) (CPB)
Trial: 22124101
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) (CP)
Trial: 18254223
Drug: Longidase (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidase (3000 IU, 10 injections, once in 5 days)
Trial: 12638810
Drug: Advance provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advance provision of oral contraceptives (20 clients)
Trial: 12638810
Drug: Standard provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard provision of oral contraceptives (280 clients)
Trial: 9430262
Drug: Multivitamin/mineral supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin/mineral supplement (in a parallel trial)
Trial: 8091822
Drug: Enoximone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.75 mg/kg i.v.)
Trial: 8091822
Drug: Enoximone (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.075 mg/kg i.v.)
Trial: 8091822
Drug: Enoximone (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (oral administration over one week)
Trial: 8091822
Drug: Gallopamil (Ca(++)-blocker)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (Ca(++)-blocker)
Trial: 14747389
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg folic acid
Trial: 29878267
Drug: 1.13 mg
RxNorm normalized name: B12/levomefolate calcium/B-6 2 mg-1.13 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.13 mg l-5-MTHF
Trial: 24070102
Drug: Issued only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Issued only a prescription
Trial: 21397769
Drug: Fenofibrate/pravastatin 160/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate/pravastatin 160/40 mg FDC
Trial: 17301734
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 mg)
Trial: 14557148
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (n = 28)
Trial: 11095435
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg androstenedione (ASD) three times daily
Trial: 8623961
Drug: Ondansetron 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.075 mg/kg
Trial: 1543677
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of terbinafine
Trial: 1543677
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of terbinafine
Trial: 1543677
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of terbinafine
Trial: 1543677
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of terbinafine
Trial: 3897535
Drug: Piroxicam 10-20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 10-20 mg once daily
Trial: 3897535
Drug: Indomethacin 75-125
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75-125 mg in divided doses
Trial: 31079275
Drug: Prolonged-release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release melatonin mini-tablets (PedPRM; 2–5 mg)
Trial: 19995670
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus bupropion
Trial: 19995670
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus placebo
Trial: 15517433
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (5000 mg per day)
Trial: 7552480
Drug: Didanosine sachets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine sachets (250 mg or 167 mg twice daily for at least 1 month)
Trial: 7552480
Drug: Didanosine chewable/dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine chewable/dispersible tablets (200 mg or 125 mg after conversion from sachets)
Trial: 7552480
Drug: Low-dose ddI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ddI (sachets, 167 mg; tablets, 125 mg)
Trial: 7552480
Drug: High-dose ddI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ddI (sachets, 250 mg; tablets, 200 mg)
Trial: 6109568
Drug: Halazepam (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halazepam (80 to 160 mg)
Trial: 6109568
Drug: Clorazepate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate (15 to 30 mg)
Trial: 31714322
Drug: 0.2 mg/mL
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/mL oxycodone plus 0.1% ropivacaine